| Kevin M Kelly Jr, | |
|
5555 Grossmont Center Drive, La Mesa, CA 91942-3019 | |
| (619) 644-4401 | |
| Not Available |
| Full Name | Kevin M Kelly Jr |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 5555 Grossmont Center Drive, La Mesa, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811924764 | NPI | - | NPPES |
| A71711 | Medicaid | CA | |
| 00A717110 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A71711 (California) | Primary |
| Entity Name | Emergency Services Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699725069 PECOS PAC ID: 6204720196 Enrollment ID: O20051215000870 |
News Archive
A new study has examined the effects on the heart of treating multiple narrowed arteries - rather than just one - at the time of a heart attack.
Researchers have linked newly discovered gene mutations to some cases of the progressive fatal neurological disease amyotrophic lateral sclerosis - ALS, also known as Lou Gehrig's disease. Shedding light on how ALS destroys the cells and leads to paralysis, the researchers found that mutations in this gene affect the structure and growth of nerve cells.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.
Understanding and replicating the diverse ways in which cellular proteins fold and interconnect is key to understanding life processes and major disorders, such as Parkinson's disease.
› Verified 7 days ago
| Entity Name | Alvarado Emergency Medical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285811992 PECOS PAC ID: 0042396251 Enrollment ID: O20080328000280 |
News Archive
A new study has examined the effects on the heart of treating multiple narrowed arteries - rather than just one - at the time of a heart attack.
Researchers have linked newly discovered gene mutations to some cases of the progressive fatal neurological disease amyotrophic lateral sclerosis - ALS, also known as Lou Gehrig's disease. Shedding light on how ALS destroys the cells and leads to paralysis, the researchers found that mutations in this gene affect the structure and growth of nerve cells.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.
Understanding and replicating the diverse ways in which cellular proteins fold and interconnect is key to understanding life processes and major disorders, such as Parkinson's disease.
› Verified 7 days ago
| Entity Name | San Diego Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194429233 PECOS PAC ID: 1052771698 Enrollment ID: O20230714001172 |
News Archive
A new study has examined the effects on the heart of treating multiple narrowed arteries - rather than just one - at the time of a heart attack.
Researchers have linked newly discovered gene mutations to some cases of the progressive fatal neurological disease amyotrophic lateral sclerosis - ALS, also known as Lou Gehrig's disease. Shedding light on how ALS destroys the cells and leads to paralysis, the researchers found that mutations in this gene affect the structure and growth of nerve cells.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.
Understanding and replicating the diverse ways in which cellular proteins fold and interconnect is key to understanding life processes and major disorders, such as Parkinson's disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin M Kelly Jr, Po Box 12170, Westminster, CA 92685-2170 Ph: (877) 818-6102 | Kevin M Kelly Jr, 5555 Grossmont Center Drive, La Mesa, CA 91942-3019 Ph: (619) 644-4401 |
News Archive
A new study has examined the effects on the heart of treating multiple narrowed arteries - rather than just one - at the time of a heart attack.
Researchers have linked newly discovered gene mutations to some cases of the progressive fatal neurological disease amyotrophic lateral sclerosis - ALS, also known as Lou Gehrig's disease. Shedding light on how ALS destroys the cells and leads to paralysis, the researchers found that mutations in this gene affect the structure and growth of nerve cells.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.
Understanding and replicating the diverse ways in which cellular proteins fold and interconnect is key to understanding life processes and major disorders, such as Parkinson's disease.
› Verified 7 days ago
Brendan J Lee, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5555 Grossmont Center Dr, La Mesa, CA 91942 Phone: 619-644-4401 | |
Christa Ann Landowska Arefieva, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5555 Grossmont Center Dr, La Mesa, CA 91942 Phone: 619-740-6000 | |
David Miles, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5555 Grossmont Center Dr, La Mesa, CA 91942 Phone: 619-740-6000 | |
Dr. Jack J Springer, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5555 Grossmont Center Dr, La Mesa, CA 91942 Phone: 619-710-4145 | |
John Kim, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5555 Grossmont Center Dr, La Mesa, CA 91942 Phone: 619-740-6000 | |
Dr. Tania Portillo, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5555 Grossmont Center Dr, La Mesa, CA 91942 Phone: 619-740-6000 | |
Joseph Witkin, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5555 Grossmont Center Drive, La Mesa, CA 91942 Phone: 619-644-4401 |